A CONCEPT FOR BEST-PRACTICE IN THERAPEUTIC DRUG MONITORING (TDM) FOR KIDNEY TRANSPLANT (K-TX): RESULTS FROM Q-PERIOR STUDY

被引：2
|
作者：
Ossa, D. [1 ]
Becker, G. [2 ]
Bayer, S. [2 ]
机构：
[1] Novartis Pharmaceut, Basel, Switzerland
[2] Q Perior AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1484
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK29
引用
收藏
页码：A513 / A513
页数：1
相关论文
共 3 条
  • [1] Therapeutic drug monitoring in clinical practice of early career psychiatrists in Europe: EPA ECPC TDM study results
    Schoretsanitis, G.
    EUROPEAN PSYCHIATRY, 2023, 66 : S54 - S54
  • [2] Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study
    E. M. H. Schmitz
    S. Benoy - De Keuster
    A. J. L. Meier
    V. Scharnhorst
    R. A. M. Traksel
    M. A. C. Broeren
    L. J. J. Derijks
    Clinical Rheumatology, 2017, 36 : 2129 - 2134
  • [3] Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study
    Schmitz, E. M. H.
    Benoy-De Keuster, S.
    Meier, A. J. L.
    Scharnhorst, V.
    Traksel, R. A. M.
    Broeren, M. A. C.
    Derijks, L. J. J.
    CLINICAL RHEUMATOLOGY, 2017, 36 (09) : 2129 - 2134
1